Inhalation Sciences’ news roundup: 2.4 MSEK sale, new patent, upcoming China installation
With a major 2.4 MSEKsale, a new European patent and the upcoming installation of ISAB’s first PreciseInhale® system in China – September and October 2018 have been eventful and dynamic for Sweden’s inhalation R&D innovators. Read our news round up here:
ZICCUM AB SHARE ISSUE OVERSUBSCRIBED 234% before listing on Spotlight
ISAB spinout company Ziccum attracted 1,000 new shareholders ahead of its listing on Spotlight. Ziccum’s technology can formulate liquid biologic therapies and vaccines – as dry powders. Making them more cost-effective and easy-to-transport. CEO Göran Conradson: ”It’s gratifying that the new issue
has been fully subscribed and we can now begin speeding up the development of our projects.”
NEW ORDER WORTH 2.4 MSEK FROM EUROPEAN-BASED GLOBAL CORPORATION
In September ISAB received an order for a PreciseInhale® system plus two in vitro modules worth 2.4 MSEK. ”This order is the result of a successful, earlier research collaboration where we were able to deliver important data to the customer’s development project. We’re delighted with the result,” says CEO Lena Heffler.
NEW FRONTIERS: ISAB SET TO INSTALL FIRST PRECISEINHALE® IN CHINA
ISAB will soon travel to Chengdu, China to install PreciseInhale® at the WestChina-Frontier PharmaTech Co., Ltd, one of the country’s leading providers of non-clinical GLP drug safety and efficacy evaluations. “For us this is a major breakthrough,” says ISAB Product & Sales Manager Mikael Mikko, “having a
first installation inAsia is an enormous opportunity and we’re excited to meet and work with the WCFP team in China.”
TOP 3 CEO PICKS FROM MVIS 2018: PRECLINICAL PRECISION IN THE SPOTLIGHT
Pre-clinical data, precision and approval was in the spotlight at this year’s MVIC Symposium in Lund this October. Did you miss it? Here’s our CEO Lena Heffler’s pick of the TOP 3 Presentations.
BREATHABLE BIOLOGICS IN BARCELONA
ISAB CEO Lena Heffler created interest at the Inhalation and Driug Respiratory Products 2018 Conference in Barcelona in September. Developing respirable biologics was a hot topic, so ISAB’s precision dosing methodology , generating aerosols from very small amounts of delicate substance, drew interest and attention.
EUROPEAN PATENT FOR XPOSEALI IN VITRO 3D CELL CULTURING MODULE
61583EP: that’s the new European patent number for our cell culturing module XposeALI ®. ”It delivers precise data early on, and dramatically reduces the number of animals needed for lung research,” says ISAB CEO Lena Heffler.
